JITC

Could the menagerie of the gut microbiome really cure cancer? Hope or hype
Muhammad Bilal Abid

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 92; DOI: 10.1186/s40425-019-0561-9
Monalizumab: inhibiting the novel immune checkpoint NKG2A
Thorbald van Hall, Pascale André, Amir Horowitz, Dan Fu Ruan, Linda Borst, Robert Zerbib, Emilie Narni-Mancinelli, Sjoerd H. van der Burg, Eric Vivier

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 263; DOI: 10.1186/s40425-019-0761-3
Perilesional edema in brain metastases: potential causes and implications for treatment with immune therapy
Thuy T. Tran, Amit Mahajan, Veronica L. Chiang, Sarah B. Goldberg, Don X. Nguyen, Lucia B. Jilaveanu, Harriet M. Kluger

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 200; DOI: 10.1186/s40425-019-0684-z
Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients
Adam E. Snook, Trevor R. Baybutt, Bo Xiang, Tara S. Abraham, John C. Flickinger, Terry Hyslop, Tingting Zhan, Walter K. Kraft, Takami Sato, Scott A. Waldman

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 104; DOI: 10.1186/s40425-019-0576-2
Nivolumab in chemotherapy-resistant cervical cancer: report of a vulvitis as a novel immune-related adverse event and molecular analysis of a persistent complete response
Florence Baettig, Tatjana Vlajnic, Marcus Vetter, Katharina Glatz, Jürgen Hench, Stephan Frank, Michel Bihl, Roberto Lopez, Michael Dobbie, Viola Heinzelmann-Schwarz, Céline Montavon

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 281; DOI: 10.1186/s40425-019-0742-6
A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer
Lucia D’Amico, Ulrike Menzel, Michael Prummer, Philipp Müller, Mélanie Buchi, Abhishek Kashyap, Ulrike Haessler, Alexander Yermanos, Rémy Gébleux, Manfred Briendl, Tamara Hell, Fabian I. Wolter, Roger R. Beerli, Iva Truxova, Špíšek Radek, Tatjana Vlajnic, Ulf Grawunder, Sai Reddy, Alfred Zippelius

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 16; DOI: 10.1186/s40425-018-0464-1
Targeting of M2-like tumor-associated macrophages with a melittin-based pro-apoptotic peptide
Chanju Lee, Hyunju Jeong, Younghyeon Bae, Kyungmoon Shin, Sinwoo Kang, Hwikyung Kim, Jayoung Oh, Hyunsu Bae

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 147; DOI: 10.1186/s40425-019-0610-4
A good response of refractory mantel cell lymphoma to haploidentical CAR T cell therapy after failure of autologous CAR T cell therapy
Tongjuan Li, Yuanyuan Zhang, Dan Peng, Xia Mao, Xiaoxi Zhou, Jianfeng Zhou

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 51; DOI: 10.1186/s40425-019-0529-9
Radiation myelitis after pembrolizumab administration, with favorable clinical evolution and safe rechallenge: a case report and review of the literature
Marcela Carausu, Arnaud Beddok, Adriana Langer, Nicolas Girard, François-Clément Bidard, Marie-Ange Massiani, Damien Ricard, Luc Cabel

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 317; DOI: 10.1186/s40425-019-0803-x
Cancer targeting by TCR gene-engineered T cells directed against Kita-Kyushu Lung Cancer Antigen-1
Bridget Marcinkowski, Sanja Stevanović, Sarah R. Helman, Scott M. Norberg, Carylinda Serna, Benjamin Jin, Nikolaos Gkitsas, Tejas Kadakia, Andrew Warner, Jeremy L. Davis, Lisa Rooper, Christian S. Hinrichs

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 229; DOI: 10.1186/s40425-019-0678-x

Main menu

JITC

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

JITC

Pages